Abstract Oligoribonucleotide conjugates and the corresponding siRNA duplexes against tumor necrosis factor carrying one, two, or four glucose and galactose residues at the 5 -end have been prepared using phosphoramidite chemistry. Carbohydrate-modified siRNA duplexes have similar inhibitory properties than unmodified RNA duplexes in HeLa cells transfected with oligofectamine. When HeLa cells were treated with siRNA carrying one, two, or four glucose residues without oligofectamine, no inhibition was observed. The inhibitory properties of siRNA carrying galactose residues without transfecting agent were tested on HuH-7 cells that have abundant asialoglycoprotein receptors. In these cells siRNA carrying galactose residues have slight anti-TNF inhibitory properties (25% in the best case) that are eliminated if the receptors are blocked with a competitor. These results demonstrate receptor-mediated uptake of siRNA carrying galactose residues, although the efficacy of the process is not enough for efficient RNA interference experiments.
Introduction
Chemically synthesized DNAs and RNAs have shown promising results as potential drugs [1, 2] . In these cases, nucleic acids are used for the inhibition of a specific gene by blocking gene translation or gene transcription or by stimulating the degradation of a particular messenger RNA. In the antisense strategy, synthetic oligonucleotides complementary to the messenger RNA of a given gene are used to inhibit translation of mRNA to protein [1, 3, 4] . On the other hand, small interfering RNA duplexes (siRNA) are used to inhibit a specific gene expression by the RNA interference (RNAi) mechanism. This is a cellular post-transcriptional gene silencing mechanism induced by a double-stranded siR-NA. In this strategy, one of these strands binds to a protein called RISC, and the complex formed is able to cleave the complementary mRNA sequence so that the corresponding protein is not formed [5] [6] [7] . Although large efforts have been devoted in the development of novel siRNA derivatives for gene silencing, the clinical potential of siRNA is still limited mainly due to low stability and inefficient delivery of siRNAs.
Chemical modification of DNA or RNA strands has been addressed as one promising strategy to solve these inconvenients [8] [9] [10] . Conjugation with different molecules such as lipids, peptides, aptamers, or polymers has been used to improve pharmacokinetic properties of siRNA without decreasing activity [9] . Synthesis of carbohydrate conjugates is a potential alternative to enhance oligonucleotide uptake using sugar binding membrane receptors to mediate cell entry [10, 11] . Oligonucleotide delivery in the form of covalent conjugates with carbohydrates is not as well explored as in the form of non covalent complexes [10] . Because the interaction between individual carbohydrates and lectins is rather weak, multivalent carbohydrate moieties linked to oligonucleotides may enhance the affinity. In the antisense strategy, galactosylated PEG-conjugates of oligonucleotide phosphorothioates have been shown to enhance uptake by galactose-specific asialoglycoprotein receptor-mediated endocytosis [12] . Multivalent carbohydrates conjugates have been described to increase interaction of carbohydrates-cellular receptors [13] [14] [15] [16] . Oishi et al. [17] described the synthesis of siRNA conjugates with lactose and polyethylene glycol at the 3 -end of the passenger strand. This modification improved gene inhibition in hepatoma cells. Glycotargeting is considered a valuable method to enhance delivery of therapeutic oligonucleotides. Moreover, selectivity between different cell types can be achieved if different carbohydrate binding receptors are expressed. This is the case of a membrane-active polymer with N -acetyl galactosamine covalently attached that preferentially accumulated the oligonucleotides in hepatocyte cells whereas if mannose is attached to the polymer the dsDNA goes preferentially to nonparenchymal and Kupffer cells, which possess mannose receptors, and away from hepatocytes [18] .
Synthesis of oligonucleotides conjugates with carbohydrates has been reviewed [19, 20] . There are three main protocols reported for the solid-phase synthesis of glycoconjugates. Carbohydrate phosphoramidite coupling is the oldest and one of the most used so far [13] [14] [15] [21] [22] [23] . Synthesis of oligonucleotide glycoconjugates can also be performed using a 1,3-dipolar cycloaddition ("click reaction") of sugar azides and support-anchored alkynylated oligonucleotides [24] . Moreover, sugar oligonucleotide conjugates have also been prepared by solid-phase oximation with carbohydrate mono-substitution [25] or displaying sugar multivalency [26] . Few examples for carbohydrate-RNA conjugates have been described. In these cases, sugar attachment has been carried out using an amide bond [27] , an oxime bond [28] , a 3,4-diethoxy-3-cyclobutene-1, 2-dione as linker [29] , or a long functional spacer built with an amide bond (containing sugar and spacer) and a michael reaction between the sugar acrylate derivative and a 5 -thiol-modified RNA [17] .
In this article we describe, for first time, the synthesis of carbohydrate conjugates of oligoribonucleotides (1-6) using phosphoramidite chemistry (Scheme 1). These modifications are introduced to the passenger strand of the siRNA for the inhibition of tumor necrosis factor (TNF-α) protein, which is involved in apoptosis, inflammation, and immunity processes [30] . We envisioned that the introduction of multiple carbohydrates (glucose or galactose) at the 5 -terminus of the passenger strand may favor cellular uptake by receptormediated endocytosis as the number of carbohydrate residues is increased.
Experimental section

Oligonucleotides
The following RNA sequences were obtained from commercial sources (Sigma-Proligo, Dharmacon): sense or passenger scrambled 5 -CAGUCGCGUUUGCGACUGGdT-dT-3 , antisense or guide scrambled 5 -CCAGUCGCAA-ACGCGACUG-dT-dT-3 , antisense or guide anti-TNFα: 5 -GAGGCUGAGACAUAGGCAC-dT-dT-3 and sense or passenger anti-TNFα: 5 -GUGCCUAUGUCUCAGCCUCdT-dT-3 . RNA monomers in capital letters, dT represents thymidine. The anti-TNFα siRNA has been previously described to efficiently downregulate murine TNFα mRNA [30] .
To a solution of the tetra-O-acetylglucopyranosyl bromide [31] 
3-[(2,3,4,6-Tetra-O-acetyl-β-d-glucopyranosyloxy)]propyl (2-cyanoethyl) (N,N-diisopropyl) phosphoramidite (8)
Diisopropylethylamine (DIEA) (0.040 mL, 0.228 mmol) and 2-cyanoethyl-N , N -diisopropylamino-chlorophosphoramidite (20 µL, 0.092 mmol) were added to a solution of compound 7 (25.0 mg, 0.061 mmol) in anhydrous CH 2 Cl 2 (2 mL) at room temperature under an argon atmosphere. After 1.0 h, no starting material was observed. Solvent was then removed and the crude was purified by
Scheme 1 Structure of the carbohydrate oligoribonucleotide conjugates prepared. RNA seq is passenger anti-TNF-α sequence: 5 -GUG-CCUAUGUCUCAGCCUC-dT-dT-3 silica gel column chromatography using hexane-ethyl acetate 
Synthesis of oligoribonucleotide-carbohydrate conjugates
Oligoribonucleotide carrying carbohydrates at the 5 -end were synthesized by a DNA synthesizer (Applied Biosystems 3400) using 2-cyanoethyl phosphoramidites and polystyrene solid supports (LV200). The following sequences were prepared:
DB stands for the symmetric doubler phosphoramidite obtained from commercial sources (Glen Research); C3 stands for -CH 2 CH 2 CH 2 -OPO − 2 -;C2 for -CH 2 CH 2 -OPO − 2 -; and dT for thymidine. The synthesis of carbohydrate phosphoramidites of Glucose-C2 (9) and Galactose-C2 (10) is described in [14, 15] whereas details for the preparation of Glucose-C3 phosphoramidite (8) are described above. Guanosine was protected with the dimethylaminomethylidene group, cytidine was protected with the acetyl group and adenosine with the benzoyl group. The 2 -OH protecting group for the RNA monomers was the tbutyldimethylsilyl (TBDMS) group. The phosphoramidites were dissolved in dry acetonitrile (0.1 M), and a modified cycle was used with increased coupling time (10 min). The solid supports were treated with concentrated aqueous ammonia-ethanol (3:1) for 1 h at 55 • C. After filtration of the solid supports, the supports were washed with ethanol, and the combined solutions were evaporated to dryness. Sequences were treated with 0.15 mL of triethylamine hydrofluoride/triethylamine/N -methylpyrrolidone (4:3:6) for 2.5 h at 65 • C to remove the t-butyldimethylsilyl groups. The reactions were stopped by addition of 0.3 mL of isopropoxytrimethylsilane and 0.75 mL of ether. The resulting mixtures were mixed with the vortex and cooled at 4 • C. A precipitate was formed that was centrifugated at 7000 rpm, 5 min at 4 • C. The precipitates were washed with ether and centrifuged again. The residues were dissolved in water, and the conjugates were purified by HPLC. HPLC conditions were: column: Nucleosil 120-10 C 18 Cell culture, transfection, and cellular assays HeLa cells were cultured under standard conditions: 37 • C, 5% CO 2 , Dulbecco's Modified Eagle Medium, 10% fetal bovine serum, 2mM l-glutamine, supplemented with penicillin (100 U/mL) and streptomycin (100 mg/mL). All in vitro experiments were conducted at 40-60% confluence. HeLa cells were transfected with 250 ng of murine expressing TNF-α plasmid using lipofectin (Invitrogen) according to the manufacturer's instructions. One hour following transfection murine TNF-α expressing HeLa cells were transfected with 50 nM of siRNA (5 -GUGCCUAUGUCUCAGCCUC-dTdT-3 /5 GAGGCUGAGACAUAGGCAC-dT-dT-3 , [30] ) against TNF-α, using oligofectamine (Invitrogen). TNF-α concentration was determined from cell culture supernatant by enzyme-linked immunoabsorbent assay kit (Bender MedSystems) according to the manufacturer's instructions.
Results and discussion
Synthesis of oligoribonucleotide carrying glucose and galactose
Among the different approaches described to prepare carbohydrate-oligonucleotide conjugates [19, 20] , we selected the protocol based on the coupling of a sugar phophoramidite to oligonucleotides on a solid support. This approach has been previously used in our group to introduce several sugars in DNA [14, 15] . We have extended this approach to prepare RNA-carbohydrate conjugates that possess one, two, and four glucose or galactose moieties. Glucose and galactose phosphoramidites carrying C2 and C3 spacers (Scheme 2) were synthesized in two steps: classical glycosylation from their corresponding bromo peracetylated sugars and ethylene glycol or propylene glycol and subsequent standard phosphoramidite chemistry as described in [14, 15] . Oligoribonucleotide carrying glucose and galactose at the 5 -end were synthesized. using the appropriate carbohydrate phosphoramidites (Scheme 2) and the commercial dendrimer symmetric doubler phosphoramidite. We selected the 21mer RNA sequence 5 -GUGCCUAUGUCUCAGCCUCdT-dT-3 for the introduction of one or several glucose or galactose moieties at the 5 -end. This RNA sequence is the passenger strand of a siRNA described to downregulate TNF-α [30] . Oligonucleotides presented a major peak with some impurities (Fig. 1 ) that were easily separated by HPLC obtaining the desired conjugates in good yields after HPLC purification. As described in [14] , some side products were observed after the synthesis of the branched oligonucleotides that lack one or two glucose or galactose residues. It is described that phosphoramidite couplings after branching are somehow less efficient [32] , but this fact did not prevent obtaining pure RNA conjugates with two and four glucose or galactose units. Mass spectrometry analysis confirms the expected molecular weight. Denaturation melting curves of siRNA duplexes formed by mixing unmodified guide strand and passenger RNA strands 1,2,5, and 6 show little differences (experimental section) when compared with unmodified siRNA. These results indicate that the presence of carbohydrates at the 5 -end of the passenger strand do not affect hybridization properties of modified RNA strands.
Inhibition of TNF-α
Tumor necrosis factor (TNF-α) was selected as a target for RNA interference studies. This protein is a major mediator of apoptosis as well as inflammation and immunity, and it has been implicated in the pathogenesis of a wide spectrum of human diseases. Therefore, the inhibition of TNF-α is of special interest especially for the development of antiflammatory drugs. Oligoribonucleotide sequences carrying carbohydrates at the 5 -end of the passenger strand were annealed with equimolar amounts of the unmodified guide strand, and the resulting duplexes were used in the inhibition of the expression of the TNF-α gene. HeLa cells were transfected first with the murine TNF-α plasmid using lipofectin, and 1 h later were contransfected with the siRNA duplex (50 nM) using oligofectamine. After 24 h, the amount of TNF-α produced by the cells was analyzed by enzyme-linked immunoabsorbent assay (ELISA). Figures 2 and 3 show the amount of TNF-α produced after 24 h of transfection of 50 nM siRNA-unmodified duplex (Unmodified), 50 nM of the same siRNA duplex carrying one, two, or four glucose (Fig. 2) or galactose (Fig. 3) residues at the 5 -end of the passenger strand and 50 nM of a scrambled RNA duplex control sequence (Scr). Modified and unmodified siRNA against TNF-α produced an 80-90% inhibition of the production of TNF-α when compared with the scrambled control siRNA duplex. In both cases, the presence of two or four carbohydrate residues produces a decrease of the inhibitory properties. These results indicate that the introduction of the both glucose and galactose at the 5 -end of the passenger strand of an RNA duplex is well tolerated by the RNAi machinery in HeLa cells although branching somehow reduces the inhibitory properties of the resulting siRNA duplex.
In addition, we have analyzed the inhibition of the TNF-α production by the siRNA duplexes carrying glucose without using oligofectamine in HeLa cells (Fig. 4) . In this case, there is no inhibition of the TNF-α production indicating that the siRNA duplexes carrying one, two, or four glucose residues are unenable to enter HeLa cells. In order to evaluate the potential uptake of siRNAs carrying galactose, human hepatoma HuH-7 cells were used. These cells have abundant asialoglycoprotein receptors as shown by incubation of α-d-galactopyranosyl-TRITCalbumine (data not shown). HuH-7 cells were transfected with the murine TNF-α plasmid using lipofectin, and 1 h later were treated with the corresponding siRNA duplexes (100 nM) without transfecting agent. After 48 h, the amount of TNF-α produced by the cells was analyzed by ELISA (Fig. 5) . A small inhibition of TNF-α (up to 25%) was observed with the siRNAs carrying galactose with no significant differences between the siRNAs having 1, 2, or 4 galactoses. It has been described that transfection of galactose derivatives may be inhibited by asialofetuin [33] . In order to confirm that the small inhibitory properties of siRNAs carrying galactoses were due to asialoglycoprotein receptormediated uptake, we analyzed the amount of TNF-α produced by the HuH-7 cells in the presence of a large excess of α-d-galactopyranosyl-TRITC-albumine that is a ligand for asialoglycoprotein receptor. Figure 6 shows that in the presence of the competitor no inhibition of TNF-α is observed. These results indicate that, most probably, the inhibition of TNF-α by siRNA carrying galactose is mediated by asialoglycoprotein receptor uptake. Unfortunately the efficacy of the uptake is low for the practical use of these siRNA conjugates without transfecting agent. Ideally the carbohydrate moiety should be separated from the oligonucleotide to optimize binding efficiency [34] . However, results from antisense studies using oligonucleotide conjugates with carbohydrates in close proximity similar to our study showed good results in antisense inhibition of gene expression [35] .
In conclusion, we have studied the effect of the 5 -insertion of one, two, or four glucose or galactose units on the inhibitory properties of siRNA duplexes. siRNA duplexes covalently linked to carbohydrates can be efficiently delivered to HeLa cells, and these conjugates enter the RNAi pathway to silence gene expression as efficiently than unmodified siRNA duplexes. When HeLa cells were treated with siRNA carrying glucose residues without oligofectamine, no inhibition was observed. On the contrary, some inhibition of the expression of TNF-α was found when galactose-modified 
